Biological and Pharmacological Roles of HCA Receptors

Advances in Pharmacology

Volumn 62, Issue , 2011, Pages 219-250

  Blad, Clara C ^a   Ahmed, Kashan ^b   IJzerman, Ad P ^a   Offermanns, Stefan ^c,d  

^a LEIDEN UNIVERSITY   (Netherlands)

^b ETH ZURICH   (Switzerland)

^c MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

G protein coupled receptors; GPR109A; GPR109B; GPR81; Hydroxy carboxylic acid receptors; Nicotinic acid

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACIFRAN; ACIPIMOX; ADIPONECTIN; ANTHRANILIC ACID DERIVATIVE; ARGININE; DEXTRO PHENYLALANINE; FUMARIC ACID; G PROTEIN COUPLED RECEPTOR; HYDROXY CARBOXYLIC ACID RECEPTOR 1; HYDROXY CARBOXYLIC ACID RECEPTOR 2; HYDROXY CARBOXYLIC ACID RECEPTOR 3; INSULIN; KETONE; LACTIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE; NICOTINIC ACID; NICOTINIC RECEPTOR; PYRAZOLE DERIVATIVE; SHORT CHAIN FATTY ACID; THREONINE; TRIACYLGLYCEROL; TRYPTOPHAN DERIVATIVE; TYROSINE; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

BOOK; ENERGY METABOLISM; FATTY ACID OXIDATION; FLUSHING; GENE STRUCTURE; HUMAN; KERATINOCYTE; LANGERHANS CELL; LIPID STORAGE; MUTAGENESIS; NEGATIVE FEEDBACK; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PHYLOGENETIC TREE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION;

EID: 80052648068     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385952-5.00005-1     Document Type: Chapter

References (128)

1. Ahmed K., Tunaru S., Langhans C.D., Hanson J., Michalski C.W., Kolker S., et al. Deorphanization of GPR109B as a receptor for the beta-oxidation intermediate 3-OH-octanoic acid and its role in the regulation of lipolysis. The Journal of Biological Chemistry 2009, 284(33):21928-21933.
2. Ahmed K., Tunaru S., Offermanns S. GPR109A, GPR109B and GPR81, a family of hydroxy-carboxylic acid receptors. Trends in Pharmacological Sciences 2009, 30(11):557-562.
3. Ahmed K., Tunaru S., Tang C., Müller M., Gille A., Sassmann A., et al. An autocrine lactate loop mediates insulin-dependent inhibition of lipolysis through GPR81. Cell Metabolism 2010, 11(4):311-319.
4. Aktories K., Jakobs K.H., Schultz G. Nicotinic acid inhibits adipocyte adenylate cyclase in a hormone-like manner. FEBS Letters 1980, 115(1):11-14.
5. Aktories K., Schultz G., Jakobs K.H. Islet-activating protein prevents nicotinic acid-induced GTPase stimulation and GTP but not GTP gamma S-induced adenylate cyclase inhibition in rat adipocytes. FEBS Letters 1983, 156(1):88-92.
6. Altschul R., Hoffer A., Stephen J.D. Influence of nicotinic acid on serum cholesterol in man. Archives of Biochemistry 1955, 54(2):558-559.
7. Benyó Z., Gille A., Bennett C.L., Clausen B.E., Offermanns S. Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Molecular Pharmacology 2006, 70(6):1844-1849.
8. Benyó Z., Gille A., Kero J., Csiky M., Suchankova M.C., Nusing R.M., et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. The Journal of Clinical Investigation 2005, 115(12):3634-3640.
9. Bjarnadóttir T.K., Gloriam D.E., Hellstrand S.H., Kristiansson H., Fredriksson R., Schioth H.B. Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse. Genomics 2006, 88(3):263-273.
10. Boatman P.D., Richman J.G., Semple G. Nicotinic acid receptor agonists. Journal of Medicinal Chemistry 2008, 51(24):7653-7662.
11. Boatman P.D., Schrader T.O., Kasem M., Johnson B.R., Skinner P.J., Jung J.K., et al. Potent tricyclic pyrazole tetrazole agonists of the nicotinic acid receptor (GPR109A). Bioorganic & Medicinal Chemistry Letters 2010, 20(9):2797-2800.
12. Bodor E.T., Offermanns S. Nicotinic acid: An old drug with a promising future. British Journal of Pharmacology 2008, 153(Suppl. 1):S68-S75.
13. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. The New England Journal of Medicine 2001, 345(22):1583-1592.
14. Cai T.Q., Ren N., Jin L., Cheng K., Kash S., Chen R., et al. Role of GPR81 in lactate-mediated reduction of adipose lipolysis. Biochemical and Biophysical Research Communications 2008, 377(3):987-991.
15. Canner P.L., Furberg C.D., Terrin M.L., McGovern M.E. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). The American Journal of Cardiology 2005, 95(2):254-257.
16. Carlson L.A. Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro. Acta Medica Scandinavica 1963, 173:719-722.
17. Carlson L.A. Nicotinic acid: The broad-spectrum lipid drug. A 50th anniversary review. Journal of Internal Medicine 2005, 258(2):94-114.
18. Cayen M.N., Kallai-Sanfacon M.A., Dubuc J., Greselin E., Dvornik D. Evaluation of the lipid-lowering activity of AY-25,712 in rats. Atherosclerosis 1982, 45(3):267-279.
19. Cheng K., Wu T.J., Wu K.K., Sturino C., Metters K., Gottesdiener K., et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(17):6682-6687.
20. Cherezov V., Rosenbaum D.M., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007, 318(5854):1258-1265.
21. Costa C.G., Dorland L., Holwerda U., de Almeida I.T., Poll-The B.T., Jakobs C., et al. Simultaneous analysis of plasma free fatty acids and their 3-hydroxy analogs in fatty acid beta-oxidation disorders. Clinical Chemistry 1998, 44(3):463-471.
22. Cresci G.A., Thangaraju M., Mellinger J.D., Liu K., Ganapathy V. Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8. Journal of Gastrointestinal Surgery 2010, 14(3):449-461.
23. Deng Q.L., Frie J.L., Marley D.M., Beresis R.T., Ren N., Cai T.Q., et al. Molecular modeling aided design of nicotinic acid receptor GPR109A agonists. Bioorganic & Medicinal Chemistry Letters 2008, 18(18):4963-4967.
24. DiGirolamo M., Newby F.D., Lovejoy J. Lactate production in adipose tissue: A regulated function with extra-adipose implications. The FASEB Journal 1992, 6(7):2405-2412.
25. Ding F.X, Shen H.C., Wilsie L.C., Krsmanovic M.L., Taggart A.K., Ren N., et al. Discovery of pyrazolyl proprionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A. Bioorganic & Medicinal Chemistry Letters 2010, 20(11):3372-3375.
26. Duncan R.E., Ahmadian M., Jaworski K., Sarkadi-Nagy E., Sul H.S. Regulation of lipolysis in adipocytes. Annual Review of Nutrition 2007, 27:79-101.
27. Exton J.H. Regulation of phosphoinositide phospholipases by hormones, neurotransmitters, and other agonists linked to G proteins. Annual Review of Pharmacology and Toxicology 1996, 36:481-509.
28. Farmer J.A. Effect of extended-release niacin or ezetimibe on carotid intimal thickness: The ARBITER-HALTS Study. Current Atherosclerosis Reports 2010, 12(5):285-287.
29. Fazio S., Guyton J.R., Lin J., Tomassini J.E., Shah A., Tershakovec A.M. Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes, Obesity & Metabolism 2010, 12(11):983-993.
30. Garg A., Grundy S.M. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA: The Journal of the American Medical Association 1990, 264(6):723-726.
31. Ge H., Weiszmann J., Reagan J.D., Gupte J., Baribault H., Gyuris T., et al. Elucidation of signaling and functional activities of an orphan GPCR, GPR81. Journal of Lipid Research 2008, 49(4):797-803.
32. Gharbaoui T., Skinner P.J., Shin Y.J., Averbuj C., Jung J.K., Johnson B.R., et al. Agonist lead identification for the high affinity niacin receptor GPR109A. Bioorganic & Medicinal Chemistry Letters 2007, 17(17):4914-4919.
33. Gille A., Bodor E.T., Ahmed K., Offermanns S. Nicotinic acid: Pharmacological effects and mechanisms of action. Annual Review of Pharmacology and Toxicology 2008, 48:79-106.
34. Grundy S.M., Vega G.L., McGovern M.E., Tulloch B.R., Kendall D.M., Fitz-Patrick D., et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: Results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Archives of Internal Medicine 2002, 162(14):1568-1576.
35. Guyton J.R. Niacin in cardiovascular prevention: Mechanisms, efficacy, and safety. Current Opinion in Lipidology 2007, 18(4):415-420.
36. Hanson J., Gille A., Zwykiel S., Lukasova M., Clausen B.E., Ahmed K., et al. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. The Journal of Clinical Investigation 2010, 120(8):2910-2919.
37. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. The Lancet 2002, 360(9326):7-22. Heart Protection Study Collaborative Group.
38. Hernandez M., Wright S.D., Cai T.Q. Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice. Biochemical and Biophysical Research Communications 2007, 355(4):1075-1080.
39. Hoefnagel J.J., Thio H.B., Willemze R., Bouwes Bavinck J.N. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. The British Journal of Dermatology 2003, 149(2):363-369.
40. Hosoi T., Koguchi Y., Sugikawa E., Chikada A., Ogawa K., Tsuda N., et al. Identification of a novel human eicosanoid receptor coupled to G(i/o). The Journal of Biological Chemistry 2002, 277(35):31459-31465.
41. Imbriglio J.E., Chang S., Liang R., Raghavan S., Schmidt D., Smenton A., et al. GPR109A agonists. Part 1: 5-Alkyl and 5-aryl-pyrazole-tetrazoles as agonists of the human orphan G-protein coupled receptor GPR109a. Bioorganic & Medicinal Chemistry Letters 2009, 19(8):2121-2124.
42. Imbriglio J.E., Chang S., Liang R., Raghavan S., Schmidt D., Smenton A., et al. GPR109A agonists. Part 2: Pyrazole-acids as agonists of the human orphan G protein-coupled receptor GPR109A. Bioorganic & Medicinal Chemistry Letters 2010, 20(15):4472-4474.
43. Irukayama-Tomobe Y., Tanaka H., Yokomizo T., Hashidate-Yoshida T., Yanagisawa M., Sakurai T. Aromatic D-amino acids act as chemoattractant factors for human leukocytes through a G protein-coupled receptor, GPR109B. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(10):3930-3934.
44. Jaakola V.P., Griffith M.T., Hanson M.A., Cherezov V., Chien E.Y., Lane J.R., et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008, 322(5905):1211-1217.
45. Jacobson T.A. A " hot" topic in dyslipidemia management-" How to beat a flush" Optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. Mayo Clinic Proceedings 2010, 85(4):365-379.
46. Jansson P.A., Larsson A., Smith U., Lonnroth P. Lactate release from the subcutaneous tissue in lean and obese men. The Journal of Clinical Investigation 1994, 93(1):240-246.
47. Jeninga E.H., Bugge A., Nielsen R., Kersten S., Hamers N., Dani C., et al. Peroxisome proliferator-activated receptor gamma regulates expression of the anti-lipolytic G-protein-coupled receptor 81 (GPR81/Gpr81). The Journal of Biological Chemistry 2009, 284(39):26385-26393.
48. Jones P.M., Tjoa S., Fennessey P.V., Goodman S.I., Bennett M.J. Addition of quantitative 3-hydroxy-octadecanoic acid to the stable isotope gas chromatography-mass spectrometry method for measuring 3-hydroxy fatty acids. Clinical Chemistry 2002, 48(1):176-179.
49. Joy T., Hegele R.A. Is raising HDL a futile strategy for atheroprotection?. Nature Reviews. Drug Discovery 2008, 7(2):143-155.
50. Jung J.K., Johnson B.R., Duong T., Decaire M., Uy J., Gharbaoui T., et al. Analogues of acifran: Agonists of the high and low affinity niacin receptors, GPR109a and GPR109b. Journal of Medicinal Chemistry 2007, 50(7):1445-1448.
51. Kamanna V.S., Ganji S.H., Kashyap M.L. The mechanism and mitigation of niacin-induced flushing. International Journal of Clinical Practice 2009, 63(9):1369-1377.
52. Kamanna V.S., Kashyap M.L. Mechanism of action of niacin. The American Journal of Cardiology 2008, 101(8A):20B-26B.
53. Kappos L., Gold R., Miller D.H., Macmanus D.G., Havrdova E., Limmroth V., et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study. The Lancet 2008, 372(9648):1463-1472.
54. Kontush A., Chapman M.J. Antiatherogenic small, dense HDL-Guardian angel of the arterial wall?. Nature Clinical Practice. Cardiovascular Medicine 2006, 3(3):144-153.
55. Kostylina G., Simon D., Fey M.F., Yousefi S., Simon H.U. Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A). Cell Death and Differentiation 2008, 15(1):134-142.
56. Lai E., Waters M.G., Tata J.R., Radziszewski W., Perevozskaya I., Zheng W., et al. Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans. Journal of Clinical Lipidology 2008, 2:375-383.
57. Lee D.K., Nguyen T., Lynch K.R., Cheng R., Vanti W.B., Arkhitko O., et al. Discovery and mapping of ten novel G protein-coupled receptor genes. Gene 2001, 275(1):83-91.
58. Li G., Shi Y., Huang H., Zhang Y., Wu K., Luo J., et al. Internalisation of the human nicotinic acid receptor GPR109A is regulated by Gi, GRK2 and arrestin3. The Journal of Biological Chemistry 2010, 285:22605-22618.
59. Liu C., Wu J., Zhu J., Kuei C., Yu J., Shelton J., et al. Lactate inhibits lipolysis in fat cells through activation of an orphan G protein-coupled receptor, GPR81. The Journal of Biological Chemistry 2009, 284(5):2811-2822.
60. Lorenzen A., Stannek C., Lang H., Andrianov V., Kalvinsh I., Schwabe U. Characterization of a G protein-coupled receptor for nicotinic acid. Molecular Pharmacology 2001, 59(2):349-357.
61. Lukasova M., Malaval C., Gille A., Kero J., Offermanns S. Nicotinic acid inhibits progression of atherosclerosis through its receptor GPR109A expressed by immune cells in mice. The Journal of Clinical Investigation 2011, 121(3):1163-1173.
62. Maccubbin D., Bays H.E., Olsson A.G., Elinoff V., Elis A., Mitchel Y., et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International Journal of Clinical Practice 2008, 62(12):1959-1970.
63. Maccubbin D., Koren M.J., Davidson M., Gavish D., Pasternak R.C., Macdonell G., et al. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. The American Journal of Cardiology 2009, 104(1):74-81.
64. Maciejewski-Lenoir D., Richman J.G., Hakak Y., Gaidarov I., Behan D.P., Connolly D.T. Langerhans cells release prostaglandin D2 in response to nicotinic acid. The Journal of Investigative Dermatology 2006, 126(12):2637-2646.
65. Mahboubi K., Witman-Jones T., Adamus J.E., Letsinger J.T., Whitehouse D., Moorman A.R., et al. Triglyceride modulation by acifran analogs: Activity towards the niacin high and low affinity G protein-coupled receptors HM74A and HM74. Biochemical and Biophysical Research Communications 2006, 340(2):482-490.
66. Mandrika I., Petrovska R., Klovins J. Evidence for constitutive dimerization of niacin receptor subtypes. Biochemical and Biophysical Research Communications 2010, 395(2):281-287.
67. Martres P. HM74a agonists: Will they be the New Generation of Nicotinic Acid?. Current Topics in Medicinal Chemistry 2009, 9(5):428-435.
68. McCulloch D.K., Kahn S.E., Schwartz M.W., Koerker D.J., Palmer J.P. Effect of nicotinic acid-induced insulin resistance on pancreatic B cell function in normal and streptozocin-treated baboons. The Journal of Clinical Investigation 1991, 87(4):1395-1401.
69. McKenney J., Bays H., Koren M., Ballantyne C.M., Paolini J.F., Mitchel Y., et al. Safety of extended release niacin/laropiprant in patients with dyslipidemia. Journal of Clinical Lipidology 2010, 4(2):105-112.e101.
70. Morgan J.M., Capuzzi D.M., Guyton J.R. A new extended-release niacin (Niaspan): Efficacy, tolerability, and safety in hypercholesterolemic patients. The American Journal of Cardiology 1998, 82(12A):29U-34U. discussion 39U-41U.
71. Nomura H., Nielsen B.W., Matsushima K. Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemotactic peptide receptors. International Immunology 1993, 5(10):1239-1249.
72. Nugteren-Huying W.M., van der Schroeff J.G., Hermans J., Suurmond D. Fumaric acid therapy for psoriasis: A randomized, double-blind, placebo-controlled study. Journal of the American Academy of Dermatology 1990, 22(2 Pt. 1):311-312.
73. Oberwittler H., Baccara-Dinet M. Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment. International Journal of Clinical Practice 2006, 60(6):707-715.
74. Offermanns S. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends in Pharmacological Sciences 2006, 27(7):384-390.
75. Offermanns S., Colletti S.L., Lovenberg T.W., Semple G., Wise A., IJzerman A.P. International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and classification of hydroxy-carboxylic acid receptors (GPR81, GPR109A, and GPR109B). Pharmacological Reviews 2011, 63:269-290.
76. Owen O.E., Felig P., Morgan A.P., Wahren J., Cahill G.F. Liver and kidney metabolism during prolonged starvation. The Journal of Clinical Investigation 1969, 48(3):574-583.
77. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000, 289(5480):739-745.
78. Paolini J.F., Mitchel Y.B., Reyes R., Kher U., Lai E., Watson D.J., et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. The American Journal of Cardiology 2008, 101(5):625-630.
79. Penberthy W.T. Nicotinic acid-mediated activation of both membrane and nuclear receptors towards therapeutic glucocorticoid mimetics for treating multiple sclerosis. PPAR Research 2009, 2009:853707.
80. Peters J.U., Kuhne H., Dehmlow H., Grether U., Conte A., Hainzl D., et al. Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: Optimization of in vitro activity. Bioorganic & Medicinal Chemistry Letters 2010, 20(18):5426-5430.
81. Plaisance E.P., Lukasova M., Offermanns S., Zhang Y., Cao G., Judd R.L. Niacin stimulates adiponectin secretion through the GPR109A receptor. American Journal of Physiology. Endocrinology and Metabolism 2009, 296(3):E549-E558.
82. Qvisth V., Hagstrom-Toft E., Moberg E., Sjoberg S., Bolinder J. Lactate release from adipose tissue and skeletal muscle in vivo: Defective insulin regulation in insulin-resistant obese women. American Journal of Physiology. Endocrinology and Metabolism 2007, 292(3):E709-E714.
83. Raghavan S., Tria G.S., Shen H.C., Ding F.X., Taggart A.K., Ren N., et al. Tetrahydro anthranilic acid as a surrogate for anthranilic acid: Application to the discovery of potent niacin receptor agonists. Bioorganic & Medicinal Chemistry Letters 2008, 18(11):3163-3167.
84. Reich K., Thaci D., Mrowietz U., Kamps A., Neureither M., Luger T. Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis-a retrospective study (FUTURE). Journal der Deutschen Dermatologischen Gesellschaft 2009, 7(7):603-611.
85. Ren N., Kaplan R., Hernandez M., Cheng K., Jin L., Taggart A.K., et al. Phenolic acids suppress adipocyte lipolysis via activation of the nicotinic acid receptor GPR109A (HM74A/PUMA-G). Journal of Lipid Research 2009, 50(5):908-914.
86. Richman J.G., Kanemitsu-Parks M., Gaidarov I., Cameron J.S., Griffin P., Zheng H., et al. Nicotinic Acid receptor agonists differentially activate downstream effectors. The Journal of Biological Chemistry 2007, 282(25):18028-18036.
87. Schaub A., Futterer A., Pfeffer K. PUMA-G, an IFN-gamma-inducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily. European Journal of Immunology 2001, 31(12):3714-3725.
88. Schmidt D., Smenton A., Raghavan S., Carballo-Jane E., Lubell S., Ciecko T., et al. Pyrazole acids as niacin receptor agonists for the treatment of dyslipidemia. Bioorganic & Medicinal Chemistry Letters 2009, 19(16):4768-4772.
89. Schmidt D., Smenton A., Raghavan S., Shen H., Ding F.X., Carballo-Jane E., et al. Anthranilic acid replacements in a niacin receptor agonist. Bioorganic & Medicinal Chemistry Letters 2010, 20(11):3426-3430.
90. Schweckendiek W. Treatment of psoriasis vulgaris. Medizinische Monatsschrift 1959, 13:103-104.
91. Semple G., Skinner P.J., Cherrier M.C., Webb P.J., Sage C.R., Tamura S.Y., et al. 1-Alkyl-benzotriazole-5-carboxylic acids are highly selective agonists of the human orphan G protein-coupled receptor GPR109B. Journal of Medicinal Chemistry 2006, 49(4):1227-1230.
92. Semple G., Skinner P.J., Gharbaoui T., Shin Y.J., Jung J.K., Cherrier M.C., et al. 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): A partial agonist of the nicotinic acid receptor, G protein-coupled receptor 109A, with antilipolytic but no vasodilatory activity in mice. Journal of Medicinal Chemistry 2008, 51(16):5101-5108.
93. Senior B., Loridan L. Direct regulatory effect of ketones on lipolysis and on glucose concentrations in man. Nature 1968, 219(5149):83-84.
94. Shen H.C. Acyl hydroxypyrazoles as novel agonists for high-affinity nicotinic acid receptor GPR109A: WO2008051403. Expert Opinion on Therapeutic Patents 2009, 19(8):1149-1155.
95. Shen H.C., Colletti S.L. Novel patent publications on high-affinity nicotinic acid receptor agonists. Expert Opinion on Therapeutic Patents 2009, 19(7):957-967.
96. Shen H.C., Ding F.X., Luell S., Forrest M.J., Carballo-Jane E., Wu K.K., et al. Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor. Journal of Medicinal Chemistry 2007, 50(25):6303-6306.
97. Shen H.C., Ding F.X., Raghavan S., Deng Q., Luell S., Forrest M.J., et al. Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): A potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate. Journal of Medicinal Chemistry 2010, 53(6):2666-2670.
98. Shen H.C., Szymonifka M.J., Kharbanda D., Deng Q., Carballo-Jane E., Wu K.K., et al. Discovery of orally bioavailable and novel urea agonists of the high affinity niacin receptor GPR109A. Bioorganic & Medicinal Chemistry Letters 2007, 17(24):6723-6728.
99. Shen H.C., Taggart A.K.P., Wilsie L.C., Waters M.G., Hammond M.L., Tata J.R., et al. Discovery of pyrazolopyrimidines as the first class of allosteric agonists for the high affinity nicotinic acid receptor GPR109A. Bioorganic & Medicinal Chemistry Letters 2008, 18(18):4948-4951.
100. Skinner P.J., Cherrier M.C., Webb P.J., Sage C.R., Dang H.T., Pride C.C., et al. 3-Nitro-4-amino benzoic acids and 6-amino nicotinic acids are highly selective agonists of GPR109b. Bioorganic & Medicinal Chemistry Letters 2007, 17(23):6619-6622.
101. Skinner P.J., Cherrier M.C., Webb P.J., Shin Y.J., Gharbaoui T., Lindstrom A., et al. Fluorinated pyrazole acids are agonists of the high affinity niacin receptor GPR109A. Bioorganic & Medicinal Chemistry Letters 2007, 17(20):5620-5623.
102. Skinner P.J., Webb P.J., Sage C.R., Dang T.H., Pride C.C., Chen R., et al. 5-N, N-Disubstituted 5-aminopyrazole-3-carboxylic acids are highly potent agonists of GPR109b. Bioorganic & Medicinal Chemistry Letters 2009, 19(15):4207-4209.
103. Soga T., Kamohara M., Takasaki J., Matsumoto S., Saito T., Ohishi T., et al. Molecular identification of nicotinic acid receptor. Biochemical and Biophysical Research Communications 2003, 303(1):364-369.
104. Soudijn W., van Wijngaarden I., IJzerman A.P Nicotinic acid receptor subtypes and their ligands. Medicinal Research Reviews 2007, 27(3):417-433.
105. Stern R.H., Spence J.D., Freeman D.J., Parbtani A. Tolerance to nicotinic acid flushing. Clinical Pharmacology and Therapeutics 1991, 50(1):66-70.
106. Taggart A.K., Kero J., Gan X., Cai T.Q., Cheng K., Ippolito M., et al. (D)-beta-hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. The Journal of Biological Chemistry 2005, 280(29):26649-26652.
107. Tang H., Lu J.Y., Zheng X., Yang Y., Reagan J.D. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochemical and Biophysical Research Communications 2008, 375(4):562-565.
108. Tang Y., Zhou L., Gunnet J.W., Wines P.G., Cryan E.V., Demarest K.T. Enhancement of arachidonic acid signaling pathway by nicotinic acid receptor HM74A. Biochemical and Biophysical Research Communications 2006, 345(1):29-37.
109. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., Grace K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004, 110(23):3512-3517.
110. Taylor A.J., Villines T.C., Stanek E.J., Devine P.J., Griffen L., Miller M., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. The New England Journal of Medicine 2009, 361(22):2113-2122.
111. Thangaraju M., Cresci G.A., Liu K., Ananth S., Gnanaprakasam J.P., Browning D.D., et al. GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Research 2009, 69(7):2826-2832.
112. Tiihonen K., Ouwehand A.C., Rautonen N. Effect of overweight on gastrointestinal microbiology and immunology: Correlation with blood biomarkers. The British Journal of Nutrition 2009, 103(7):1070-1078.
113. Trujillo M.E., Scherer P.E. Adiponectin-Journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. Journal of Internal Medicine 2005, 257(2):167-175.
114. Tunaru S., Kero J., Schaub A., Wufka C., Blaukat A., Pfeffer K., et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nature Medicine 2003, 9(3):352-355.
115. Tunaru S., Lattig J., Kero J., Krause G., Offermanns S. Characterization of determinants of ligand binding to the nicotinic acid receptor GPR109A (HM74A/PUMA-G). Molecular Pharmacology 2005, 68(5):1271-1280.
116. van der Hoorn J.W., de Haan W., Berbee J.F., Havekes L.M., Jukema J.W., Rensen P.C., et al. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2008, 28(11):2016-2022.
117. van Herk T., Brussee J., van den Nieuwendijk A.M., van der Klein P.A., IJzerman A.P., Stannek C., et al. Pyrazole derivatives as partial agonists for the nicotinic acid receptor. Journal of Medicinal Chemistry 2003, 46(18):3945-3951.
118. van Veldhoven J.P.D., Blad C.C., Artsen C.M., Klopman C., Wolfram D.R., Abdelkadir M.J., et al. Structure-activity relationships of trans-substituted-propenoic acid derivatives on the nicotinic acid receptor HCA2 (GPR109A). Bioorganic & Medicinal Chemistry Letters 2011, 21:2736-2739.
119. Villines T.C., Stanek E.J., Devine P.J., Turco M., Miller M., Weissman N.J., et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): Final results and the impact of medication adherence, dose, and treatment duration. Journal of the American College of Cardiology 2010, 55(24):2721-2726.
120. Vogt A., Kassner U., Hostalek U., Steinhagen-Thiessen E. Prolonged-release nicotinic acid for the management of dyslipidemia: An update including results from the NAUTILUS study. Vascular Health and Risk Management 2007, 3(4):467-479.
121. Walters R.W., Shukla A.K., Kovacs J.J., Violin J.D., DeWire S.M., Lam C.M., et al. beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. The Journal of Clinical Investigation 2009, 119(5):1312-1321.
122. Warne T., Serrano-Vega M.J., Baker J.G., Moukhametzianov R., Edwards P.C., Henderson R., et al. Structure of a beta1-adrenergic G protein-coupled receptor. Nature 2008, 454(7203):486-491.
123. Westphal S., Borucki K., Taneva E., Makarova R., Luley C. Extended-release niacin raises adiponectin and leptin. Atherosclerosis 2007, 193(2):361-365.
124. Wise A., Foord S.M., Fraser N.J., Barnes A.A., Elshourbagy N., Eilert M., et al. Molecular identification of high and low affinity receptors for nicotinic acid. The Journal of Biological Chemistry 2003, 278(11):9869-9874.
125. Wu B., Chien E.Y., Mol C.D., Fenalti G., Liu W., Katritch V., et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010, 330(6007):1066-1071.
126. Yousefi S., Cooper P.R., Mueck B., Potter S.L., Jarai G. cDNA representational difference analysis of human neutrophils stimulated by GM-CSF. Biochemical and Biophysical Research Communications 2000, 277(2):401-409.
127. Zellner C., Pullinger C.R., Aouizerat B.E., Frost P.H., Kwok P.Y., Malloy M.J., et al. Variations in human HM74 (GPR109B) and HM74A (GPR109A) niacin receptors. Human Mutation 2005, 25(1):18-21.
128. Zingoni A., Rocchi M., Storlazzi C.T., Bernardini G., Santoni A., Napolitano M. Isolation and chromosomal localization of GPR31, a human gene encoding a putative G protein-coupled receptor. Genomics 1997, 42(3):519-523.